Company Media Investors & Corporate 2020 Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

The U.S.-listed shares of Immuron Ltd. skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the Naval Medical Research Center (NMRC) has requested..... https://www.marketwatch.com/story/immurons-stock-blasts-off-nearly-10-fold-after-partner-nmrc-seeks-pre-ind-meeting-with-fda-2020-06-09?mod=mw_quote_news

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Filter Categories

Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information